Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sylentis Piles On Another Failure In Dry Eye

Executive Summary

The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.

You may also be interested in...



Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb

The Swiss drug maker said it would sell the underperforming dry eye drug plus pipeline assets and rights to a delivery device for $2.5bn, which for Bausch + Lomb means a bigger presence in the space.

B+L/Novaliq Hope Miebo Can Stand Out In Crowded Dry Eye Field

The companies got US FDA approval for the drug, which they said is the only approved medicine that targets tear evaporation rather than tear production, though its mechanism is not fully understood.

Alcon Buys Aerie, Reaffirming Commitment To Pharma Space

With the $770m acquisition, Alcon will gain two commercial eye drop products for glaucoma and a Phase III candidate for dry eye.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel